Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887377 · ClinicalTrials.gov registry record · Phase 2
The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation
A Phase 2 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03887377 is a Phase 2 study that has completed, run by Henry Ford Health System. The registered enrollment target is 22 participants.
The verdict
NCT03887377, a Phase 2 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
1. Test the ability of botulinum toxin type A, when injected into the surgical incision at the time of surgery, to decrease postoperative scar scores compared to control (normal saline) in a double-blinded randomized control trial. 2. Investigate the mechanism of BTXa effects of scar formation by measuring micro RNA profiles at two time points in the healing process.
Interventions
- OTHER Normal saline
- DRUG Botulinum Toxins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03887377
The ClinicalTrials.gov registry entry for NCT03887377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT03887377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03887377 about?
NCT03887377 is a clinical study titled "The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation". 1. Test the ability of botulinum toxin type A, when injected into the surgical incision at the time of surgery, to decrease postoperative scar scores compared to control (normal saline) in a double-blinded randomized control trial. 2. Investigate the mechanism of BTXa effects of scar formation by me...
What is the current status of trial NCT03887377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2019-06-10. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT03887377?
The interventions under investigation include: Normal saline (OTHER), Botulinum Toxins (DRUG).
Who is sponsoring clinical trial NCT03887377?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.